Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dynorphin/Kappa Opioid Receptor Signaling Role in Ketamine's Anti-suicidal Ideation Effect

NCT07139106 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT07139106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07139106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dynorphin/Kappa Opioid Receptor Signaling Role in Ketamine's Anti-suicidal Ideation Effect
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)